Balyasny Asset Management’s Moderna MRNA Stock Holding History

Balyasny Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-76,400	Closed	-$2.25M	–	3282
2025 Q4	$2.25M	Buy	76,400 +59,700	+357%	+$1.62M	﹤0.01%	1797
2025 Q3	$431K	Sell	16,700 -145,600	-90%	-$4.06M	﹤0.01%	2450
2025 Q2	$4.48M	Buy	162,300 +145,600	+872%	+$3.83M	0.01%	1339
2025 Q1	$473K	Sell	16,700 -200,000	-92%	-$7.1M	﹤0.01%	2289
2024 Q4	$9.01M	Buy	216,700 +188,200	+660%	+$9M	0.01%	1007
2024 Q3	$1.9M	Buy	28,500 +15,200	+114%	+$1.4M	﹤0.01%	1688
2024 Q2	$1.58M	Buy	+13,300	New	+$1.68M	﹤0.01%	1617
2023 Q4	–	Sell	-455,000	Closed	-$47M	–	2746
2023 Q3	$47M	Buy	455,000 +325,000	+250%	+$36.3M	0.1%	285
2023 Q2	$15.8M	Buy	+130,000	New	+$17.3M	0.03%	612
2022 Q4	–	Sell	-5,000	Closed	-$591K	–	3057
2022 Q3	$591K	Buy	+5,000	New	+$759K	﹤0.01%	1984
2022 Q2	–	Sell	-4,000	Closed	-$689K	–	3012
2022 Q1	$689K	Sell	4,000 -42,000	-91%	-$7.07M	﹤0.01%	1732
2021 Q4	$11.7M	Buy	+46,000	New	+$13.4M	0.04%	593
2021 Q3	–	Sell	-2,500	Closed	-$587K	–	2256
2021 Q2	$587K	Buy	+2,500	New	+$447K	﹤0.01%	1497
2020 Q3	–	Sell	-1,600,000	Closed	-$103M	–	1478
2020 Q2	$103M	Buy	+1,600,000	New	+$87.6M	0.89%	8

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Balyasny Asset Management's MRNA Position: Q1 2026 in Review

Balyasny Asset Management reduced its Moderna (MRNA) stake by 62% in Q1 2026, selling an estimated $401K and leaving 5,191 shares worth $264K. The position accounts for ﹤0.01% of the portfolio, ranked #2611.

Balyasny Asset Management first reported a position in MRNA in Q2 2019 and has held it in 15 quarters since. The position peaked at $72.3M in Q3 2023. 723 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

Balyasny Asset Management held 5,191 shares of Moderna worth $264K as of Q1 2026.
Balyasny Asset Management sold 8,599 Moderna shares in Q1 2026, an estimated $401K.
Moderna made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #2611 holding.
Balyasny Asset Management first reported a position in Moderna in Q2 2019 and has held it in 15 quarters since.
Balyasny Asset Management's Moderna position peaked at $72.3M in Q3 2023.
723 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.